Home self-administration of omalizumab for chronic spontaneous urticaria

Denman, Sarah; Ford, K.L.; Toolan, J.; Mistry, Anoop; Corps, Claire; Wood, Philip; Savic, Sinisa

doi:10.1111/bjd.15074

Cited by 27 publications

(25 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although speculative, this could be explained with younger patients being more active in social, school, and work life; thus prolonged treatment duration and required hospital visits for injections might affect them more. Self-administration of omalizumab at home, as described previously (Denman et al, 2016;, might be a good alternative for such patients. It would also be interesting to evaluate the effect of age on patient reported outcomes in larger studies with a longer follow-up period.…”

Section: Discussionmentioning

confidence: 99%

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Salman

Demir

Bekiroğlu

2019

Dermatologic Therapy

View full text Add to dashboard Cite

Background Omalizumab is a third‐line treatment for chronic spontaneous urticaria (CSU). However, the real‐life data on the impact of omalizumab on CSU‐related quality of life (QoL) remain scarce. Objectives To investigate the impact of omalizumab on QoL and its predictors in CSU. A retrospective cohort study was done. The response to therapy was evaluated using urticaria activity score over 7 days (UAS7) and urticaria control test (UCT); the impairment in QoL was assessed using dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU‐Q2oL). Results Forty‐two patients were included. All scores improved from baseline to first month and remained stable at the third month of treatment (p < .001). The gender, age, and angioedema had no significant effect on QoL, but the complete responders (UAS7:0–1) had better improvement rates in all scores compared to others. The baseline UAS7, DLQI, and CU‐Q2oL scores were lower at the baseline in complete responders (p = .0001). Conclusions A rapid and continual improvement in QoL was obtained with omalizumab treatment. A better UAS7, UCT, DLQI, and CU‐Q2oL score at the baseline might be a predictor of a better response to omalizumab and more improvement in QoL.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

Salman

Demir

Bekiroğlu

2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…In the absence of any data indicating a potential for harm, it would be reasonable to continue administration of biologic agents during the COVID-19 pandemic in patients for whom such agents are clearly indicated and have been effective. 44,45 In summary, understanding of the intersection between asthma and COVID-19 is evolving. There are currently scant data to indicate the degree of risk (or protection) from disease, and no data to support strong recommendations for or against specific asthma treatments.…”

Section: Specific Conditionsmentioning

confidence: 99%

COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic

Shaker

Oppenheimer

Grayson

et al. 2020

The Journal of Allergy and Clinical Immunology: In Practice

280

419

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…In December 2018, home self-administration of omalizumab became licensed. Prior to this license change, three immunology centres within the UK developed home treatment pathways for patients with CSU, one of which was described in an earlier publication 1. This update describes all three UK centres’ experience of self-administration or carer administration of omalizumab at home for CSU and the pathways used to supply omalizumab.…”

Section: Introductionmentioning

confidence: 99%

Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria

et al. 2019

View full text Add to dashboard Cite

IntroductionDue to perceived risk of anaphylaxis, home treatment with omalizumab has been limited. Within the UK, most centres administer omalizumab in a hospital setting. However, the reported prevalence of anaphylaxis is low and in December 2018 home treatment became licensed. A home treatment pathway was previously reported by one UK centre, and this update describes three UK centres’ experience of home omalizumab treatment.MethodsThe medical records of omalizumab patients were retrospectively reviewed.ResultsA total of 137 adult patients have received home omalizumab treatment; home treatment duration 0–44 months. There was no increase in adverse effects seen in patients treated at home. There were no reported adherence issues and no reduction in efficacy. Patients report they prefer home treatment due to increased flexibility and reduced impact on daily life/work.ConclusionHome treatment with omalizumab is a safe and effective alternative to hospital administration.

show abstract

Home self-administration of omalizumab for chronic spontaneous urticaria

Cited by 27 publications

References 4 publications

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real‐life data

COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic

Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria

Contact Info

Product

Resources

About